Dermatology最新文献

{"title":"Comparison of Acute Generalized Exanthematous Pustulosis with Maculopapular Rash in a Swiss Patient Cohort: A Single-Center Retrospective Study.","authors":"Fabienne Fröhlich, Dominik Wetzstein, Mirjam C Nägeli, Thomas Kündig, Emmanuel Contassot, Barbara Meier-Schiesser","doi":"10.1159/000545324","DOIUrl":"https://doi.org/10.1159/000545324","url":null,"abstract":"<p><strong>Introduction: </strong>Acute generalized exanthematous pustulosis (AGEP) is a rare cutaneous drug reaction characterized by the sudden appearance of non-follicular sterile pustules on an erythematous background which is accompanied by fever and peripheral blood neutrophilia. While the clinical differentiation between AGEP and common delayed-type drug hypersensitivity reactions, such as maculopapular rash (MPR), is well-defined, the pathomechanism, causative drugs, and other possible contributing factors remain poorly studied to date.</p><p><strong>Methods: </strong>In this retrospective case-control study we compared clinical data on suggested causative drugs, drug testing, and comorbidities between a group of 52 patients with a confirmed diagnosis of AGEP (both clinically and histologically) and a group of 63 patients with confirmed MPR.</p><p><strong>Results: </strong>Evaluation of the causative drugs revealed that beta-lactam antibiotics represent the most common culprit drug in both AGEP and MPR, while antimycotics (p = 0.002), glucocorticoids (p = 0.0106) and NSAIDs (p = 0.0064) were significantly more frequent in AGEP. Skin patch tests and in vitro lymphocyte transformation tests (LTT) showed higher positivity rates in MPR compared to AGEP, with all non-beta-lactam antibiotics tested with LTT leading to negative results in AGEP. A detailed analysis of comorbidities suggested a possible association between diseases of the upper gastrointestinal tract and AGEP.</p><p><strong>Conclusions: </strong>This study highlights the differences in causative drugs and comorbidities between AGEP and MPR, emphasizing the need for further research to enhance the understanding and management of AGEP.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-24"},"PeriodicalIF":3.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and monocyte/lymphocyte ratio: A post hoc analysis of three randomised clinical trials.","authors":"Niamh Kearney, Patricia Gorecki, Lorenzo Acciarri, Jozefien Buyze, Alianu Akawung, Joseph F Merola, Brian Kirby","doi":"10.1159/000545148","DOIUrl":"https://doi.org/10.1159/000545148","url":null,"abstract":"<p><p>Background Psoriasis is associated with an increased risk of cardiovascular disease (CVD). Previous studies have found that treatment with tumour necrosis factor or interleukin (IL)-17 inhibitors leads to reductions in the systemic inflammation biomarkers neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and monocyte/lymphocyte ratio (MLR). Objectives The primary aim of this study was to evaluate changes in NLR, PLR and MLR with guselkumab compared with placebo (VOYAGE I/II), adalimumab (VOYAGE I/II) and secukinumab (ECLIPSE). The secondary aims were to assess correlation with disease severity, C-reactive protein (CRP) levels and treatment response. Methods This was a post hoc analysis of VOYAGE I, VOYAGE II and ECLIPSE Phase III randomised trial data on guselkumab for moderate-to-severe plaque psoriasis. NLR, PLR and MLR were evaluated at baseline and Week 16 in VOYAGE I and II and at baseline and Week 12 in ECLIPSE. Mean changes were compared between groups using a Student's t-test; Pearson's test was used for correlation analyses. Results VOYAGE I included 837 randomised patients, VOYAGE II 992 randomised patients and ECLIPSE 1048 randomised patients. In VOYAGE I, NLR (p=0.011), PLR (p=0.015) and MLR (p=0.004) decreased significantly following 16 weeks of guselkumab treatment vs. placebo. In VOYAGE II, reductions in NLR (p=0.003), PLR (p=0.006) and MLR (p=0.001) were greater at Week 16 in patients treated with guselkumab vs. placebo. Treatment with adalimumab was associated with a greater reduction (p<0.001) in the three biomarkers vs. guselkumab, while secukinumab resulted in a similar reduction in NLR, PLR and MLR compared with guselkumab (p=0.413, 0.650 and 0.498, respectively). All biomarkers weakly correlated with Psoriasis Area Severity Index (PASI) at baseline and showed modest correlations with CRP levels. Biomarkers in patients who were PASI90 responders were consistent between all active treatment groups at baseline. Conclusions Guselkumab is a highly efficacious treatment for plaque psoriasis; the study has demonstrated the potential benefit of treatment with guselkumab in reducing systemic inflammation as measured by NLR, PLR and MLR, which appeared to be independent of psoriasis response, suggesting that reducing systemic inflammation with guselkumab may decrease CVD risk. Clinical trial registration VOYAGE I: NCT02207231; VOYAGE II: NCT02207244; ECLIPSE: NCT03090100.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-35"},"PeriodicalIF":3.0,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethics of Artificial Intelligence-Based Therapy for Treating Psychological Comorbidities Associated with Dermatological Conditions.","authors":"Ryan Scheinkman, Sheila Sharifi, Keyvan Nouri","doi":"10.1159/000545579","DOIUrl":"10.1159/000545579","url":null,"abstract":"","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-2"},"PeriodicalIF":3.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kaposi's Sarcoma, Epidemiology and Clinical Characteristics in a Tertiary Hospital: A Cross-Sectional Study.","authors":"Fanny Carolina López Jiménez, Jorge Alberto González Torres, Sirenia Castro Molina, Andrea Malagón Liceaga, Linda García Hidalgo","doi":"10.1159/000545022","DOIUrl":"10.1159/000545022","url":null,"abstract":"<p><strong>Introduction: </strong>Kaposi's sarcoma (KS) is a rare soft tissue tumor linked to human herpesvirus 8, a recognized oncogenic virus. Five distinct clinical presentations have been identified, with the epidemic type being the most prevalent and notably associated with human immunodeficiency virus (HIV). A delayed diagnosis significantly compromises patient prognosis and survival rates.</p><p><strong>Methods: </strong>This article aimed to describe the epidemiological and clinical characteristics of KS cases diagnosed through histological examination between 2007 and 2023 in our dermatology department, after a comprehensive review of electronic medical records.</p><p><strong>Results: </strong>A total of 52 cases were identified, with 51 cases corresponding to the epidemic type (associated with HIV infection) and only one to the classic type. Men were predominantly affected, all cases being of the epidemic type. The most prevalent topography was the lower extremities, with nodular lesions being the most frequent morphology. Half of the cases presented as a disseminated form, while the remaining half exhibited localized manifestations. In both groups, 50% had previously undergone combined antiretroviral therapy. Gastrointestinal involvement occurred in 8 cases. No deaths were associated with KS.</p><p><strong>Conclusions: </strong>Due to its often asymptomatic nature, KS can easily go unnoticed. Recognizing the significance of early detection is crucial, emphasizing the necessity for prompt intervention, accurate staging, and vigilant follow-up protocols.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-5"},"PeriodicalIF":3.0,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From the Cochrane Library: Interventions for Nail Psoriasis.","authors":"Michael J Diaz, Kaya L Curtis, Jasmine T Tran, Phyllis I Spuls, Marjorie E Montanez-Wiscovich, Shari R Lipner","doi":"10.1159/000545021","DOIUrl":"10.1159/000545021","url":null,"abstract":"","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-4"},"PeriodicalIF":3.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tattoo Ink Products and Pigments 2018-2019 Upfront the New EU-REACH Regulation: Danish Golden Benchmark Study of 108 Studios and 39,687 Clients Tattooed with Inks from 109,720 Ink Bottles.","authors":"Jørgen Serup, Bjørn Christian Severin, Esben Hammershøy","doi":"10.1159/000543455","DOIUrl":"10.1159/000543455","url":null,"abstract":"<p><strong>Introduction: </strong>The new EU regulation on tattoo inks in force January 2022 in a hitherto unregulated market marks a historical change. The study aim was to register tattoo inks de facto used in studios before the new EU regulation and establish a historical reference to tattoo customer exposure, ink toxicology assessment, clinical complications, and the impact on tattooing businesses.</p><p><strong>Method: </strong>A tattooist-operated electronic system (InkBase) for ink registration required by law is used in Denmark since 2018. A local database in studios refers to a central database. Clients, sessions, ink bottles, brand name, and pigment color index (CI) are registered. Person's data protection is respected. Tracing harmful inks is possible, with public warning.</p><p><strong>Results: </strong>Registrations from 108 studios employing about 700 tattooists were collected from March 2018 to 2019. 39,687 clients were tattooed in 50,604 sessions, using colors from 109,720 ink bottles. 10,833 were CI-labelled identifying the pigment. 98.1% of inks originated from USA. Detailed statistics on inks and pigments used are provided as a benchmark showing the spontaneous use and preference of \"old\" tattoo inks before the EU regulation compulsory to member states introduced dramatic restrictions difficult to follow.</p><p><strong>Conclusions: </strong>Denmark can, having detailed ink registration enforced by law and having a commonly used electronic registration system reporting to a central server, function as an index country in future surveillance of use of tattoo inks in studios, toxicology aspects and the impact of regulatory intervention on the tattooing industry, with a large sample of data collected in 2018-2019.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-13"},"PeriodicalIF":3.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Risk Factors Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease in Psoriatic Patients.","authors":"Kirley Küçük, Christophe Moreno, Hassane Nijmi, Mathieu Daoud, Dillon Mintoff, Fabienne Willaert, Farida Benhadou","doi":"10.1159/000541796","DOIUrl":"10.1159/000541796","url":null,"abstract":"<p><strong>Introduction: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common cause of chronic liver disease. Patients suffering from psoriasis are at an increased risk of developing MASLD. Psoriasis and MASLD share a pro-inflammatory cytokine milieu; however, it is still unclear whether these conditions are related through shared metainflammatory processes or shared comorbidities such as obesity, diabetes, insulin resistance, and metabolic syndrome. The aim of our study was to better characterize the anthropometric and metabolic profile of psoriatic patients with MASLD.</p><p><strong>Methods: </strong>We conducted a prospective, single-center, cross-sectional study between June 2014 and August 2017. Recruitment was restricted to adult patients with psoriasis. Blood analysis, liver ultrasonography, and a FibroScan were performed. Blood investigations, baseline anthropometric measurements, and components of fatty liver disease (hepatic ultrasound, FibroScan) were assessed.</p><p><strong>Results: </strong>A total of 100 patients were recruited, of which, 43% (65.1% men, n = 28) were diagnosed with MASLD. The mean BMI was significantly higher in MASLD than in non-MASLD (27.7 kg/m2 vs. 30.1 kg/m2, p =< 0.001). The mean waist circumference in MASLD patients was significantly higher than in non-MASLD patients (105.6 cm vs. 97.2 cm, p = 0.005). There was no significant difference between the mean age of both patient groups (50.4 vs. 47.3 years, p = 0.26). Psoriatic arthritis was more prevalent in MASLD than in the non-MASLD group (14.3% vs. 1.8%, p = 0.004). Biochemical analysis revealed significantly higher C-peptide level in patients with MASLD compared with patients without MASLD (2.5 vs. 1.6 ng/mL, p = 0.036). Moreover, MASLD patients were found to have a lower HDL level and higher glycemia, triglyceridemia, cholesterol, and LDL levels than non-MASLD patients. A total of 16.3% of patients with MASLD had fibrosis stage ranging from F2 to F4 based on liver stiffness measurement compared with only 10.6% of patients without MASLD.</p><p><strong>Discussion: </strong>We identified parameters which were more prevalent in patients with psoriasis having MASLD, specifically a high BMI, elevated triglyceride levels, decreased HDL levels, and an elevated level of C-peptide. Patients with psoriasis and MASLD were more likely to suffer from comorbid psoriatic arthritis, despite having similar psoriasis disease severity as measured by PASI.</p><p><strong>Conclusion: </strong>This study highlights the importance of screening patients with psoriasis for MASLD to prevent the progression to liver fibrosis.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"92-100"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ehlers-Danlos Syndromes and Related Disorders: Diagnostic Challenges and the Need for an Interdisciplinary Patient Care in Germany.","authors":"Nikolaus Kernich, Franziska Peters, Julia Schreml, Oliver Semler, Manuel Koch, Eckhard Schönau, Michael Huntgeburth, Peer Eysel, Thomas Krieg, Esther von Stebut-Borschitz, Iliana Tantcheva-Poór","doi":"10.1159/000542026","DOIUrl":"10.1159/000542026","url":null,"abstract":"<p><strong>Introduction: </strong>Ehlers-Danlos syndromes (EDS) represent a group of heritable connective tissue disorders characterized by skin hyperelasticity, joint hypermobility and generalized tissue fragility. Many patients remain undiagnosed years after initial symptoms and an accurate diagnosis is difficult despite all efforts. Currently, Germany lacks a patient registry and a specialized EDS centre.</p><p><strong>Methods: </strong>In early 2020, a dermatological-orthopaedic EDS outpatient service was established at the University Hospital of Cologne. Medical records of all patients presenting in 2020 were retrospectively analysed.</p><p><strong>Results: </strong>Forty-three adults were examined. Fifteen patients were diagnosed with EDS (different types), 13 with hypermobility spectrum disorder, and 1 with likely Loeys-Dietz syndrome (LDS) based on patient history and a suspicious variant in the gene TGFBR1. Excluding hypermobile EDS (6 patients), molecular confirmation was achieved in a total of 4 of 9 patients. The combination of symptomatic generalized hypermobility and skin manifestations was diagnostic in more than two-thirds of the EDS patients. Arterial involvement (aneurysms, dissection and rupture) and distinctive cutaneous signs (thin translucent skin with haematomas) indicated vascular EDS and LDS in altogether 3 patients.</p><p><strong>Conclusion: </strong>With the present analysis, we discuss our diagnostic approach in patients with a suspected diagnosis of EDS in order to raise awareness of this rare group of genodermatoses and review recent developments in EDS nosology.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"124-132"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Territory-Wide Follow-Up of Primary and Secondary Extramammary Paget Disease of 2 Decades: Effects of Local Disease on Survival.","authors":"Joanna Ka Man Ng, Agnes Wai Sze Chan, Christina Man-Tung Cheung, Edric Chi-Ching Ip, Paul Cheung Lung Choi, Wendy Wan Hang Lau, Jacqueline Ho Sze Lee, Joshua Jing Xi Li","doi":"10.1159/000541394","DOIUrl":"10.1159/000541394","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Extramammary Paget disease (EMPD) is an uncommon malignant cutaneous neoplasm that are divided into primary and secondary forms. In this multicenter study, histologically proven cases of primary and secondary EMPD were reviewed for clinical outcomes with subgroup analysis for secondary EMPD.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methodology: &lt;/strong&gt;Cases of EMPD were identified from pathology report of the involved institutions over a period of over 2 decades. Cases of secondary EMPD were identified review of case notes, radiology, and pathology reports. Clinicopathological and outcome data were retrieved for statistical analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 109 cases were retrieved, including 19 cases of secondary EMPD, most commonly associated with colorectal (n = 6), anal (n = 5), and prostatic carcinomas (n = 3). A difference was observed between older age and secondary (vs. primary) EMPD (p = 0.016), but no differences were seen in other clinico-demographical parameters. Male sex (p = 0.018), age over 60 years (p = 0.004), and involvement of margins (resectable) (p = 0.018) were associated with shorter OS. For DSS, involvement of margins (p = 0.009) was an adverse predictor. Secondary EMPD had a shorter DSS than primary EMPD (p = 0.005). Multivariable analysis confirmed all above associations (p &lt; 0.05). In subgroup analysis for secondary EMPD, margin involvement remained associated with shorter OS (p = 0.007) and DSS (p = 0.003).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Secondary EMPD is associated with poorer outcomes. Margin involvement is strong and independent indicator of shorter OS and DSS, including secondary EMPD. Resectability is a strong predictor of favorable outcome and excision with clear margins should be attempted when surgically feasible.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Extramammary Paget disease (EMPD) is an uncommon malignant cutaneous neoplasm that are divided into primary and secondary forms. In this multicenter study, histologically proven cases of primary and secondary EMPD were reviewed for clinical outcomes with subgroup analysis for secondary EMPD.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methodology: &lt;/strong&gt;Cases of EMPD were identified from pathology report of the involved institutions over a period of over 2 decades. Cases of secondary EMPD were identified review of case notes, radiology, and pathology reports. Clinicopathological and outcome data were retrieved for statistical analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 109 cases were retrieved, including 19 cases of secondary EMPD, most commonly associated with colorectal (n = 6), anal (n = 5), and prostatic carcinomas (n = 3). A difference was observed between older age and secondary (vs. primary) EMPD (p = 0.016), but no differences were seen in other clinico-demographical parameters. Male sex (p = 0.018), age over 60 years (p = 0.004), and involvement of margins (resectable) (p = 0.018) were associated with shorter OS. For DSS, involvement of marg","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"72-79"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11793087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Hidradenitis Suppurativa and Gout: A Propensity Score-Matched Cohort Study.","authors":"Hui-Chin Chang, Tsu-Man Chiu, Ru-Yin Tsai, Chen-Pi Li, Yu-Lun Wu, Shiu-Jau Chen, Shuo-Yan Gau","doi":"10.1159/000541969","DOIUrl":"10.1159/000541969","url":null,"abstract":"<p><strong>Introduction: </strong>While an association between hidradenitis suppurativa (HS) and inflammatory arthritis has been reported in clinical studies, the potential link between HS and gout remains uncertain. As HS and gout share common immunological pathways, we conducted a retrospective cohort study to determine whether HS patients are at an increased risk of developing gout in the future.</p><p><strong>Methods: </strong>This retrospective multicenter cohort study obtained information through the US collaborative network, a subset of the TriNetX research network. Patients diagnosed with HS between January 01, 2005, and December 31, 2017, were recruited, and a 1:1 propensity score matching was conducted to identify appropriate controls. The hazard ratio (HR) for the new-onset gout in HS patients was subsequently calculated.</p><p><strong>Results: </strong>Compared to individuals without HS, those with HS were associated with a 1.39-fold higher risk (95% confidence interval [CI], 1.20, 1.62) of developing new-onset gout within 5 years after the index date. This association remained significant in shorter follow-up times and sensitivity analyses utilizing different matching models. For both male and female HS patients, the risk of developing new-onset gout within 5 years after the index date was statistically significant, with respective HRs of 1.61 (95% CI, 1.28, 2.02) for males and 1.41 (95% CI, 1.11,1.78) for females.</p><p><strong>Conclusion: </strong>HS patients are at a high risk of developing gout within 5 years after an HS diagnosis while comparing with non-HS controls.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"19-26"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}